Daxid

Quick links to important sections

Daxid

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Daxid

Quick Facts

Property Description
Active Ingredient Sertraline (as Sertraline Hydrochloride)
Form Tablets, Oral Concentrate Solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Supports mood stabilization and mental balance
Origin Synthetic Compound

What Type of Medicine is Daxid (Sertraline)?

Daxid is a medicinal product containing the active ingredient Sertraline, which is classified as an antidepressant and belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class. This designation means that Sertraline works selectively to modulate the brain’s chemical environment. The key action of this medicine is to support the stabilization of mood and the regulation of emotional responses by influencing the system responsible for the neurotransmitter serotonin (5-HT).

As an SSRI, Sertraline's effectiveness in enhancing mental equilibrium and processing is widely clinically recognized and supported by pharmacological studies. This action is consistent with its role as a serotonin reuptake blocker, a mechanism that distinguishes it from older, non-selective antidepressants.


Composition and Form: What is Daxid Made of?

The medicine is a single-ingredient product composed of the synthetic compound Sertraline, typically manufactured as the salt Sertraline Hydrochloride. This active compound is prepared for oral administration and is available in distinct dosage form(s): solid tablets (often film-coated) and an oral concentrate solution. The availability of both tablets and an oral concentrate is a feature that allows for flexibility in use. The oral concentrate includes pharmaceutical excipients, such as alcohol and glycerin, to ensure the stable delivery of the Sertraline.

Regulatory References

  1. MedlinePlus Drug Information on Sertraline
  2. Sertraline: StatPearls

What side effects are possible with Daxid?

Possible Side Effects and Safety Information

Daxid, a selective serotonin reuptake inhibitor (SSRI), carries a Boxed Warning from regulatory authorities concerning the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) when starting treatment or increasing the dose. Close monitoring is essential during these periods.


Common Adverse Reactions

The most frequently reported adverse reactions, documented in clinical trials as occurring in ge5% of patients and at a rate at least twice that of placebo, include those affecting the gastrointestinal, nervous, and reproductive systems. These common events (ranging from ge1/100 to <1/10 incidence in regulatory texts) primarily are nausea, diarrhea/loose stool, insomnia, tremor, increased sweating (hyperhidrosis), decreased appetite, and male sexual dysfunction, such as ejaculation failure.


Serious Risks and Safety Restrictions

Serious and clinically significant adverse reactions documented in official labeling include the potential for Serotonin Syndrome, a potentially life-threatening condition, especially when co-administered with other serotonergic agents, including Monoamine Oxidase Inhibitors (MAOIs). Use with MAOIs, including linezolid and intravenous methylene blue, is strictly contraindicated, requiring a 14-day washout period before starting Daxid. Other serious risks involve increased potential for bleeding, the activation of mania or hypomania, seizures, and angle-closure glaucoma.


Population and Discontinuation Notes

Daxid should be used with caution in patients with hepatic impairment, often necessitating lower dosing. Third-trimester use during pregnancy may increase the risk of persistent pulmonary hypertension in the newborn. Upon treatment cessation, a gradual dose reduction (tapering) is mandatory to mitigate the risk of discontinuation syndrome symptoms, which may include sensory and mood disturbances.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Daxid (Sertraline) requires immediate medical attention. Regulatory documents stress that aggressive medical treatment is necessary due to the risk of severe outcomes. Overdose may present with a range of documented clinical manifestations primarily affecting the Central Nervous System and cardiovascular system. Reported signs often include somnolence, gastrointestinal disturbances (nausea, vomiting), tachycardia (rapid heart rate), tremor, agitation, and confusion.

Element Official Regulatory Statement
Urgent Action Required Seek immediate medical attention or call a national Poison Control Center.
Severe Risks Serotonin Syndrome, seizures, and coma, especially when ingested with other substances or alcohol.
Antidote Status No specific antidote is known for Sertraline overdose.

The profile includes life-threatening risks, notably Serotonin Syndrome and cardiac abnormalities such as QTc prolongation. Because of these risks, management is strictly symptomatic and supportive, focusing on maintaining the airway and stabilizing vital signs. Medical professionals may consider gastrointestinal decontamination, such as administering activated charcoal, to minimize drug absorption. Continuous monitoring, including ECG surveillance, is often recommended following an overdose. The severity of the presentation may depend on the ingestion of concomitant medications.

Therapeutic Uses of Daxid

What Daxid Treats: Main Uses and Benefits

Daxid (Sertraline) is generally considered relevant across multiple therapeutic domains, applied where additional symptomatic support is needed. Its therapeutic applications are focused on assisting to ease the overall symptom load of persistent emotional and psychiatric manifestations.

The medicine is commonly used to help with core symptoms of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Premenstrual Dysphoric Disorder (PMDD).

Daxid is often used during phases when symptoms create noticeable functional strain, such as pronounced panic attacks, intrusive thoughts, or persistent low mood. This supportive role may help patients cope more steadily with difficult emotional episodes.

“The medicine supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.”


Quick Fact: Support for Functional Strain

Area of Relief Symptom Type Benefit Focus
Mood Persistent sadness, loss of pleasure Helps support emotional balance and is relevant for easing depressive symptoms.
Anxiety Pronounced panic attacks, social fear Contributes to improved comfort during periods of heightened fear.
Cognition Unwanted, recurrent thoughts (obsessions) May assist with managing intrusive thought patterns and rituals.

Regulatory References

  1. U.S. Food & Drug Administration (FDA)

Eligibility and Restrictions for Use

Daxid (Sertraline) use is defined by specific population eligibility rules established by governmental regulatory bodies.

Who Must Not Use Daxid

Use is contraindicated and must not occur in patients with a known hypersensitivity to sertraline or any component of the formulation. It is also strictly prohibited for patients taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid, or the antipsychotic drug Pimozide. For the oral concentrate solution form, use is also contraindicated for patients taking Disulfiram.

Eligibility by Age and Condition

Adults (18 years and older) are approved for use across all labeled indications. For pediatric patients, use is strictly limited to those aged 6 to 17 years only for Obsessive-Compulsive Disorder (OCD); safety and effectiveness have not been established for children under six years of age.

Specific physiological states impose restrictions. Use is not recommended in patients with moderate to severe hepatic impairment due to severely reduced clearance. Caution is required in patients with mild hepatic impairment or a history of mania. For pregnancy and lactation, use is not recommended unless the prescribing authority determines that the potential benefit outweighs the potential risk.

What should I know about interactions with other medicines?

The interaction profile for Daxid (Sertraline) is defined by officially documented prohibitions, additive pharmacodynamic effects, and pharmacokinetic alterations described in regulatory sources.

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is strictly prohibited due to the high, documented risk of Serotonin Syndrome. A mandatory 14-day washout period must elapse when switching between Daxid and an MAOI. The combination with Pimozide is also contraindicated, as regulatory studies document a significant increase in Pimozide plasma concentrations. The oral concentrate solution is further prohibited for use with Disulfiram due to the alcohol content in the formulation.

Metabolic and Pharmacodynamic Effects

Daxid is documented as a mild-to-moderate inhibitor of the enzyme Cytochrome P450 2D6 (CYP2D6), a pharmacokinetic property that may result in increased plasma concentrations (exposure) of co-administered medicines metabolized by this pathway (e.g., Propafenone). Pharmacodynamically, co-administration with other serotonergic agents (such as Triptans, Tramadol, or Lithium) can potentiate the risk of Serotonin Syndrome. Concomitant use with agents that affect hemostasis, including NSAIDs, Aspirin, and Warfarin, officially increases the documented risk of bleeding. Furthermore, the official label notes that Sertraline clearance is significantly reduced in patients with chronic mild hepatic impairment, resulting in up to a three-fold greater drug exposure. Alcohol and the herbal product St. John’s Wort are also not recommended for use concurrently.

Mechanism of Action

Primary Molecular Action: Selective Serotonin Reuptake Inhibition

Daxid's mechanism initiates with its high-affinity binding and inhibition of the Serotonin Transporter ( SERT) in the central nervous system. This action prevents the reabsorption (reuptake) of the neurotransmitter serotonin ( 5-HT) from the synaptic cleft back into the presynaptic neuron . The result is an increased concentration and duration of 5-HT signaling within the synaptic space.


Adaptive Neuroplasticity and Downstream Effects

The full mechanistic profile relies on delayed physiological adaptation emerging after chronic administration. These changes involve the gradual desensitization of 5-HT autoreceptors and the promotion of neuroplasticity through the increased expression of Brain-Derived Neurotrophic Factor ( BDNF). This process supports the structural remodeling of neural circuits and influences the functional set-point of circuits involved in affective regulation.


Modulation of Regulatory Stress Systems

Beyond reuptake inhibition, Daxid exerts systemic influence on regulatory pathways, including antagonism at the Sigma-1 (sigma 1) receptor. This activity, combined with chronic serotonergic changes, affects the responsiveness of major stress-response pathways such as the Hypothalamic-Pituitary-Adrenal (HPA) axis), influencing the sustained functional set-point of pathways mediating physiological stress reactions.

Dosage and Administration Information

How Daxid is Used: Official Administration Guidelines

This section outlines the general administration and official dosing principles for Daxid (sertraline).


Administration Route and Frequency

Daxid is approved exclusively for oral administration. The medicine is generally taken once daily, either in the morning or the evening.

Approved Dosage Form Administration Context
Tablets (25 mg, 50 mg, 100 mg) May be taken with or without food.
Oral Concentrate Solution (20 mg/mL) Must be diluted before ingestion with 4 oz of specific liquids (e.g., water, orange juice) and consumed immediately.

Official Dosing and Titration Rules

Dosage regimens are defined by the specific therapeutic use. The medicine requires a gradual titration to reach the effective maintenance dose. Dose increases should occur in increments of typically 50 mg and must be separated by an interval of at least one week.

Indication Group Typical Starting Dose Maximum Daily Dose
MDD, OCD 50 mg/day 200 mg
Panic Disorder, PTSD, SAD 25 mg/day (increased after one week) 200 mg

The maximum recommended daily dose for most uses is 200 mg.


Specific Population Rules

Dosage adjustments are officially required for certain groups. For patients with mild hepatic impairment, the recommended starting dose and the maximum dose are typically half the amounts recommended for standard adult patients. No dosage adjustment is generally necessary for patients with renal impairment.

Recent Clinical Evidence

Daxid: Recent Clinical Evidence

The research evidence for Daxid (Sertraline) primarily comes from controlled studies, including Randomized Controlled Trials (RCTs) and systematic reviews. These studies help show what has been observed so far regarding symptom measurement and change across its key indications.


Evidence for use in Major Depressive Disorder (MDD)

Research has explored the measurement of acute symptoms and recurrence frequency through short-term and long-term RCTs in adults and adolescents. Outcomes related to systemic or functional imbalance, such as depressive symptom severity, were the main focus. Research describes the observed patterns for the general adult population. However, data for certain adult subgroups, such as those with co-occurring severe chronic medical illness, often remain insufficient, and findings can be inconclusive.


Evidence for Anxiety and Related Conditions

Daxid was studied for conditions involving heightened symptoms, including Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD). Studies explored acute and long-term RCTs, examining outcomes like symptom intensity and the frequency of episodic changes across adults and children. For OCD, studies exploring higher levels of drug exposure sometimes indicated increased rates of participant discontinuing the study. For anxiety disorders like PTSD, findings were mixed, and subgroup findings are uncertain.


Long-Term Research and Gaps

Maintenance and follow-up trials have monitored how symptoms evolved over extended periods, sometimes up to 18 to 24 months, primarily for MDD and OCD. However, follow-up durations were limited in scope, and long-term effects are not fully established across all uses. Comparative evidence is lacking for direct assessment against all other available treatments, and evidence quality varies across specialized or smaller patient subgroups.

Key Studies & References

  1. Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover Study
  2. Sertraline Prevents Hypotension During Hemodialysis: A Randomized Clinical Trial (Study of a special population/comorbidity)
  3. Antidepressants and the FDA's Black-Box Warning: Determining a Rational Public Policy in the Absence of Sufficient Evidence (FDA Regulatory Context)

Frequently Asked Questions (FAQ)

Common questions about Daxid (FAQ)

Q: Why is Daxid prescribed by doctors?

Official regulatory documentation indicates that Daxid is approved for use across several conditions. These include Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD). The medicine’s use is described for these multiple specific indications.

Q: What is the main difference between Daxid and other medicines used for similar conditions?

Official documents classify Daxid as belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class. Its core action is to selectively prevent the reuptake of the neurotransmitter serotonin in the brain. This mechanism is what distinguishes it from other classes of medicines, such as older or non-selective antidepressants.

Q: Is Daxid meant to be taken long-term or short-term?

According to official product information, Daxid is described for both acute treatment to address current symptoms and for longer-term maintenance use in certain conditions. Clinical trials have monitored symptoms for extended periods, sometimes up to 18 to 24 months.

Q: Can children or adolescents use Daxid?

Use is strictly limited based on age and condition. Official documentation states that for pediatric patients, Daxid is approved only for those aged 6 to 17 years and only for Obsessive-Compulsive Disorder (OCD). Safety and effectiveness have not been established for children younger than six.

Q: What is the purpose of the different strengths of Daxid tablets?

Official dosing rules require a gradual titration to reach the effective maintenance dose of the medicine. The availability of different strengths (such as 25 mg, 50 mg, 100 mg) supports the ability to increase the daily amount in small, step-wise increments over time.

Q: Is there a maximum daily amount of Daxid described in the label?

Yes, the maximum daily amount is specified in official regulatory documentation. The maximum recommended daily dose for most approved uses of the medicine is 200 mg.

Q: What official warnings are associated with Daxid?

Official warnings include a Boxed Warning concerning the increased risk of suicidal thoughts and behaviors in young adults, adolescents, and children when starting treatment. Additional cautions address the potential for serious risks like Serotonin Syndrome, bleeding events, and the activation of mania or hypomania.

Q: Does taking Daxid affect my ability to drive or operate machinery?

Official warnings note that Daxid may cause side effects such as dizziness or drowsiness. The official warning indicates that caution is necessary regarding operating hazardous machinery or driving until the effects of the medicine are known.

Q: Is it normal to feel dizzy or lightheaded after taking Daxid?

Dizziness is documented in official adverse event tables as a reported reaction in clinical studies. This information is provided to describe observed patterns during trials.

Q: Why do some people say they feel worse when they first start Daxid?

The official label documents that some frequently reported adverse reactions tend to occur when treatment is initiated. These can include issues like nausea, diarrhea/loose stool, and insomnia.

Q: What happens if I stop taking Daxid suddenly?

Official documents require a gradual dose reduction (tapering) when stopping treatment. This tapering is mandatory to mitigate the risk of discontinuation syndrome symptoms, which may involve sensory and mood disturbances.

Q: Can Daxid cause weight gain or weight loss?

Adverse event tables from clinical trials document reports of changes in patient weight that occurred during the studies. Both increases and decreases in weight are documented as reported reactions.

Q: How quickly should I expect Daxid to start working?

Official documents state that the full effect of the medicine involves delayed physiological adaptation in the central nervous system. This supports the structural remodeling of neural circuits.

Q: What are the signs of an allergic reaction to Daxid?

Signs of a severe hypersensitivity reaction may include hives, rash, swelling, or difficulty breathing. Any suspicion of hypersensitivity is documented as a contraindication to use.

Q: Does Daxid affect sleep patterns?

The official label lists insomnia (difficulty sleeping) as one of the most frequently reported adverse reactions. This event occurred in a significant percentage of patients in clinical trials, suggesting a common observation regarding sleep.

Q: Can Daxid affect blood pressure readings?

Adverse event tables document reports of changes in blood pressure, including hypertension (high blood pressure), that occurred during clinical trials.

Q: Is Daxid safe for elderly patients?

Official product information includes clinical trial data that describes observed patterns in patients ge 65 years of age. Generally, no dosage adjustments are typically necessary based solely on age, but caution is advised in the elderly population.

Q: Can Daxid affect fertility in men or women?

Regulatory studies conducted in animals have documented effects on male reproductive function at exposure levels higher than those used in clinical settings. The potential effect on human fertility, however, is not fully established.

Q: Why is my friend taking Daxid for a different problem than me?

Official regulatory documents indicate that Daxid is approved for use across multiple therapeutic indications, meaning it can be prescribed for several distinct conditions. These indications include Major Depressive Disorder, Obsessive-Compulsive Disorder, and various anxiety disorders.

Q: Does alcohol interact negatively with Daxid?

Official regulatory sources state that the concurrent use of Daxid and alcohol is not recommended. This advice is given due to the potential for negative interactions.

Q: Can I take over-the-counter pain relievers while using Daxid?

The official label notes that using Daxid concurrently with medicines that affect blood clotting (hemostasis), such as NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and Aspirin, officially increases the documented risk of bleeding.

Q: Does Daxid interact with common cold or flu medications?

Official sources caution that combining Daxid with other serotonergic agents can increase the risk of Serotonin Syndrome. Also, concurrent use with agents that affect hemostasis (often present in OTC flu products) increases the documented risk of bleeding.

Q: Are there any known interactions between Daxid and herbal supplements?

Regulatory documents specifically state that the herbal product St. John’s Wort is not recommended for concurrent use with Daxid. This prohibition is due to the potential for interactions.

Q: Why do some people need to take Daxid with food?

Studies of Daxid have shown that taking the medicine with food results in a small increase in the drug's exposure in the body compared to taking it without food. This is a pharmacokinetic observation described in official documents.

Q: How long does Daxid stay in your system?

The average elimination half-life of Daxid in the body is documented in official pharmacokinetic data to be approximately 26 hours. This value represents the rate at which the medicine is processed and cleared from the system.

Q: Is Daxid safe to use during pregnancy?

Use during pregnancy is generally not recommended unless a prescribing authority determines the potential benefit outweighs the potential risk. Official documents specifically note that third-trimester use may increase the risk of persistent pulmonary hypertension in the newborn.

Q: Are there studies on Daxid's use in nursing mothers?

Official information indicates that the medicine is excreted into human breast milk. Use during lactation is generally not recommended unless the prescribing authority determines the potential benefit outweighs the potential risk.

Q: Is Daxid available as a generic medicine?

Daxid is a brand name for the active ingredient Sertraline. Sertraline is the generic chemical name for the medicine and is available in generic formulations.

Q: How can I find the official prescribing information for Daxid?

The official prescribing information for Daxid (Sertraline) is typically available on the websites of national regulatory agencies. These include the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). You can often find the full document by searching the active ingredient name.

Q: What kind of studies led to the approval of Daxid?

Research evidence supporting the regulatory approval of Daxid comes primarily from Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored outcomes related to symptom measurement across its key approved indications.

Q: How is the safety of Daxid monitored after it is approved?

Regulatory agencies maintain a continuous process known as pharmacovigilance (drug safety monitoring) following approval. This process involves the ongoing collection and evaluation of reports of adverse events and safety data.

How should Daxid be stored and disposed of?

How to Store and Dispose of Daxid?

The official storage and disposal requirements for Daxid are defined to maintain its stability and ensure safe handling.

Storage Requirements

Storage Domain Official Regulatory Statement
Temperature Store at 20 C to 25 C (68 F to 77 F); excursions permitted to 15 C to 30 C (59 F to 86 F).
Protection Keep the bottle tightly closed in its original container to protect from moisture; do not remove the desiccant.
Safety Keep Daxid and all medicines out of the reach of children.

Disposal Instructions

Unused or expired Daxid should be disposed of via a drug take-back program if one is readily available. If a take-back program is not accessible, the medication should be mixed with an unappealing substance (like dirt or cat litter), placed into a sealed plastic bag, and then discarded in the household trash. This prevents accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Daxid found in:

A-Z Index: